There are well-established disparities in cancer incidence and outcomes by race/ethnicity
that result from the interplay between structural, socioeconomic, socio-environmental …

Background Without inclusion of diverse research participants, it is challenging to
understand how study findings will translate into the real world. Despite this, a lack of …

A concerted commitment across research stakeholders is necessary to increase equity,
diversity, and inclusion (EDI) and address barriers to cancer clinical trial recruitment and …

Abstract On April 22, 2020, the FDA granted accelerated approval to sacituzumab govitecan-
hziy (TRODELVY; Immunomedics, Inc.) for the treatment of patients with metastatic triple …

A need exists to examine racial disparities in the healthcare arena and the impact on
patients with cancer. Despite ongoing efforts to increase equity in primary healthcare …

Background Racial and ethnic minorities (REMs) continue to be underrepresented in clinical
trials despite the 1993 National Institutes of Health's Revitalization Act mandating the …

PURPOSE: In general, participation rates in cancer clinical trials are very low. However,
participation rates are especially low among the socially disadvantaged and racial and …

PURPOSE: Cancer disparities persist among medically underserved populations despite
widespread efforts to address them. We describe the development of a framework for …

Although mortality from cardiovascular disease (CVD) has declined consistently in the
United States, CVD remains a major public health burden for Black US residents. 1, 2 Given …

Objectives Given the disparity that exists in enrollment of minorities to oncology clinical trials,
the objective of our study was to assess whether race is associated with willingness to …